
Aug 19, 2025, 17:00
Rahul Gosain: TROPION-Lung01 and Lung05 Study that Resulted in DatoDXd FDA Approval
Rahul Gosain, Director of Regional Infusion Services and Medical Director at Wilmot Cancer Institute, shared a post on LinkedIn:
“One page takeaway/summary from our with Jacob Sands and TROPION-Lung01 and Lung05 study that resulted in DatoDXd FDA approval on June 23, 2025 for previously treated mEGFR NSCLC!”
More posts featuring Rahul Gosain on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 19, 2025, 16:27
Aug 19, 2025, 16:17
Aug 19, 2025, 16:07
Aug 19, 2025, 15:53
Aug 19, 2025, 15:16
Aug 19, 2025, 15:10